Sigmoido-Uterine Fistula Caused by Ovarian Cancer

Brajnev Kumar Yadav1, Jin-Jian Xiang1*, Ben-Jing Cheng1, Qing-Hua Yi2

1Department of General Surgery, The First Hospital Affiliated to Yangtze University, Jingzhou, China
2Department of Gynecology, The First Hospital Affiliated to Yangtze University, Jingzhou, China
Email: *xiangjjxiangcy@sina.com, brajneyadav@gmail.com, 309802903@qq.com, 245593557@qq.com

Abstract
A 67-year-old woman presented with abdominal distension and difficulty in defecation. She had a huge mass in the left lower abdomen and hyperamylasemia with normal pancreatic-type amylase (P-AMY). Nuclear magnetic resonance and computed tomography scan revealed a huge pelvic mass, but the origin of mass wasn’t certain. After discussion with the multidisciplinary team, ultrasonography guided pathological biopsy of the mass was done. Pathological biopsy showed that the mass was poorly differentiated adenocarcinoma, which may be originated from ovary. Patient was on neo-adjuvant chemotherapy. After one and a half months of chemotherapy, the patient developed colorectal-reproductive system fistula with hyperpyrexia. Laparotomy with resection of mass, sigmoid colon, left ovary and part of uterus, proximal colostomy with closure of the distal rectum and end to end anastomosis of left ureter with DJ tube drainage (left ureter invaded by tumor confirmed intra operation) was done. Operative finding: Fistula between sigmoid colon and uterus through the tumor.

Keywords
Sigmoido-Uterine Fistula, Ovarian Cancer, Hyperamylasemia

1. Introduction
When ovarian masses are too big, especially invading the surrounding tissue, they can induce visceral fistula and sometimes difficult to clarify the origins. Some ovarian cancer may be accompanied by hyperamylasemia (elevated salivary-type amylase, S-AMY) [1]. We present a case report of patient with sigmoido-uterine fistula caused by ovarian cancer and hyperamylasemia.

2. Case Report
A 67-year-old woman presented in the department of medicine at local hospital
with loss of appetite for 1 year and weight loss about 20 kg in 2 months. She had abdominal distension and difficulty in defecation, but no abdominal pain, vomiting and diarrhea. She had a history of cholelithiasis, hypertension and pulmonary tuberculosis. Physical examination revealed a huge mass in the left lower abdomen. The patient had hyperamylasemia and normal pancreatic-type amylase (serum amylase 908 U/L, serum pancreatic-type amylase 84 U/L, urine amylase 978 U/L, urine pancreatic-type amylase 150 U/L). Routine blood test showed increased white blood cell count (16.07 × 10⁹/L) and decreased hemoglobin (82 g/L). Serum CRP was increased (139.45 mg/L). Serum CA125 (603.9 U/ml) and CA15-3 (100.6 U/ml) were increased and AFP (2.53 ng/ml), CEA (1.07 ng/ml) and CA19-9 (3.69 U/ml) were normal. A computed tomography scan (CT-scan) of the pancreas revealed cholelithiasis, the left hydroureteronephrosis, the left adrenal nodule, but no abnormalities was found in pancreas. Nuclear magnetic resonance scan (MRI-scan) of pelvis showed a huge pelvic mass, which may be originated from uterus and free fluid in the pelvic cavity.

The patient was admitted to gynecology department of our hospital for one week. Multiple re-examination of amylase (AMY) was still elevated and pancreatic-type amylases (P-AMY) were still normal. Colonoscopy was performed and revealed a huge tumor in sigmoid [Figure 1(a)] and biopsy showed necrotic tissue. Gynecological ultrasound revealed multiple uterine fibroids. Computed tomography angiography plus urography plus 3D reconstruction (CTA + CTU + 3D) considered a huge malignant tumor [11.4 cm × 11.6 cm × 11.2 cm, Figure 1(b)] in sigmoid colon, some gas in tumor, tumor blood supplied from inferior mesenteric artery [Figure 1(c)], the left lower ureter was invaded by the tumor and upper left ureter and renal pelvis were dilatated [Figure 1(d)]. In order to further clarify the diagnosis and treatment, a discussion with the multidisciplinary teams (MDTs, involving department of gynecology, general surgery, urinary surgery, oncology, gastroenterology and radiology) was performed. The discussion results: 1) Hyperamylasemia likely caused by the tumor. 2) Ultrasonography guided pathological biopsy of the mass to clear the origin of tumor, which may be originated from sigmoid or ovary or retroperitoneal tissue. 3) Tumor can’t be radically resected at present herein, it’s better to do pre-operative

Figure 1. Colonoscopy and imaging examination.
neo-adjuvant chemoradiotherapy or molecular targeted therapy according to tumor histological tissue types and origins. Pathological biopsy showed poorly differentiated adenocarcinoma, which originated from ovary, [immunohistochemistry: CK7(+), CK20(−), Villin(−), CDX2(−), CA19-9(−), CA125(+), CEA(−), Ki67(+) 70% - 80%]. The patient underwent 2 cycles of chemotherapy (3 weeks apart) for ovarian cancer with (paclitaxel 135.48 mg/m², total dose 210 mg, carboplatin 258.06 mg/m², total dose 400 mg for 3 days per cycle). After the first cycle of chemotherapy, Serum-AMY, CA125 and CA15-3 decreased and tumor obviously shrank (5.6 cm × 5.1 cm × 4.9 cm). Ten days after the second cycle chemotherapy, the stool was coming out from patient’s vagina with hyperpyrexia, which showed the patient had colorectal-reproductive system fistula. Combining with department of gynecology, general surgery and urinary surgery, laparatomy with resection of mass, sigmoid colon, left ovary and part of uterus, proximal colostomy with closure of the distal rectum and end to end anastomosis of left ureter with DJ tube drainage (left ureter invaded by tumor confirmed intra operation) was done. Operative findings: sigmoido-uterine fistula through the tumor, one end in the sigmoid colon and other end in left cornua uteri. Histological examination showed necrotic tissue. The patient recovered well and underwent post surgery adjuvant chemotherapy. One month after surgery serum-AMY, CA125 and CA15-3 dropped back to normal and CT abdomen showed no residual tumor.

3. Discussion

Human α-amylase includes salivary-type isoamylase and pancreatic-type isoamylase. Salivary-type amylase or gene is present in normal human salivary glands, thyroid, lungs and the female genital tract [2] [3]. In clinical cases, elevated salivary-type amylases are observed in many tumors such as lung cancer [4], pancreatic cancer [5], stomach cancer [6], uterine tumors [7], ovarian cancer [8] [9] [10], osteosarcoma [11], multiple myeloma [12]. In our case, the tumor originated from the ovary. The patient had hyperamylasemia and normal pancreatic-type amylase, so we can infer the patient had elevated salivary-type amylase. When the patient was hospitalized in department of medicine at local hospital with hyperamylasemia, she was once falsely diagnosed with pancreatitis. So when the patients have hyperamylasemia, especially with normal pancreatic-type amylase, we must consider possibility of amylase-producing tumors and further examine such as imaging examination and tumor markers etc should be performed.

The origin of the tumor was not certain before operation in our case. The tumor was huge and located in the pelvic cavity, may be originated from sigmoid or ovary or uterus or urinary bladder or retroperitoneal tissue. So we organized a discussion with the multidisciplinary team. We considered the discussion with the multidisciplinary teams was important to diagnose and treat complex neoplasms according to our some cases and some references [13] [14]. After the discussion with the multidisciplinary teams, the possibility of origins from uterus or urinary bladder was excluded, but the possibility of origin from sigmoid or
ovary or retroperitoneal tissue was still not certain. Combining the result of colonoscopy and biopsy (necrotic tissue), gas (maybe come from intestinal tract or caused by tumor necrosis) in tumor and tumor blood supplied from inferior mesenteric artery, sigmoid colon tumor couldn’t be excluded. Given hyperamylasemia with normal pancreatic-type amylase and rising serum CA125 and CA15-3, ovarian cancer also couldn’t be excluded. In view of location, some rare tumors originated from retroperitoneal tissue needs to be considered. To clarify the diagnosis and treatment, ultrasonography guided pathological biopsy of the mass was performed after discussion with the multidisciplinary teams. In consideration of highly unlikely radical resection of tumor, if sigmoid stromal tumor was confirmed by pathological biopsy, the patient needed molecular targeted therapy (usually with imatinib) before surgery; if tumor originated from ovarian tissues, pre-operation neo-adjuvant chemotherapy might shrink the tumor so that we could radically resect the tumor; if tumor was sigmoid carcinoma, prognosis of patient was poor. Pathological biopsy showed the tumor was poorly differentiated adenocarcinoma, which might be originated from ovary. [immunohistochemistry: CK7(+), CK20(−), Villin(−), CDX2(−), CA19-9(−), CA125(+), CEA(−), Ki67(+): 70% - 80%].

Ten days after the second cycle chemotherapy, the stool was coming out from patient’s vagina with hyperpyrexia, which showed the patient had colorectal-reproductive system fistula. During surgery, we found sigmoïd-uterine fistula through the tumor (ovarian mass, one end in the sigmoid colon and other end in left cornua uteri). So gas in tumor revealed by CT-scan before surgery may be from the fistula between sigmoid colon or uterus and tumor, not just only caused by tumor necrosis. CTA + CTU + 3D revealed tumor blood was supplied from inferior mesenteric artery, which made us suspect the tumor perhaps was originated from sigmoid colon. However the tumor was originated from ovary actually, so tumor blood vessel from inferior mesenteric artery was angiogenesis.

After the first cycle chemotherapy, Serum-AMY, CA125 and CA15-3 decreased and tumor obviously shrank. Histological examination showed necrotic tissue. Serum-AMY, CA125 and CA15-3 dropped back to normal and CT showed no residual tumor 1 month after operation. So, we considered the patient was in pathologic complete remission (PCR) after chemotherapy. The patient need follow up still under control in the future.

Acknowledgements
We appreciate the guidance given by the professor Fu Tian from department of gastrointestinal surgery.

Conflicts of Interest
The authors have no conflicts of interests relevant to this article.

References
Clinica Chimica Acta, 391, 106-111.


Submit or recommend next manuscript to SCIRP and we will provide best service for you:

- Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc.
- A wide selection of journals (inclusive of 9 subjects, more than 200 journals)
- Providing 24-hour high-quality service
- User-friendly online submission system
- Fair and swift peer-review system
- Efficient typesetting and proofreading procedure
- Display of the result of downloads and visits, as well as the number of cited articles
- Maximum dissemination of your research work

Submit your manuscript at: [http://papersubmission.scirp.org/](http://papersubmission.scirp.org/)
Or contact ym@scirp.org